Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||BGB-A425 + Tislelizumab|
BGB-A425 is an antibody that targets Tim-3, potentially resulting in enhanced anti-tumor immune response and decreased tumor growth (Cancer Res July 1 2017 (77) (13 Supplement) 2628).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BGB-A425||BGBA425|BGB A425||BGB-A425 is an antibody that targets Tim-3, potentially resulting in enhanced anti-tumor immune response and decreased tumor growth (Cancer Res July 1 2017 (77) (13 Supplement) 2628).|
|Tislelizumab||BGB-A317||Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98||Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03744468||Phase Ib/II||BGB-A425 + Tislelizumab||Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors||Recruiting||USA||2|